Literature DB >> 11497252

Bone morphogenetic protein-2 and type IV collagen expression in psammoma body forming ovarian cancer.

Y Kiyozuka1, H Nakagawa, H Senzaki, Y Uemura, S Adachi, Y Teramoto, T Matsuyama, K Bessho, A Tsubura.   

Abstract

Psammoma bodies (PBs), characterized as calco-spherules with concentric laminations, are common in serous tumors of the ovary. However, there is no agreements as to how the PBs are formed. Bone morphogenetic protein-2 (BMP-2) has recently been proposed to be involved in the calcification of tumor cells and recent electron microscopic studies demonstrated the presence of type IV collagen in PBs. Based on this evidence, we postulated a possibe role for BMP-2 and type IV collagen in the formation of PBs in ovarian cancer. We examined the expression of BMP-2 and typle IV collagen by immunohistochemistry and reverse transcription PCR (RT-PCR) in PBs-forming (NK-211) and -non-forming (SHIN-3, KF-1, A2780, KK-92, KOC-2S, SKOV-3, OMC-3, MN-1, EC, and KEN-3) ovarian cancer cell lines in vitro and in surgical specimens of serous adenocarcinoma (SA) with/without PBs and mucinous adenocarcinoma (MA) of the ovary. Cellular growth of cell lines was also evaluated by their doubling time in vitro. Transcripts for BMP-2 mRNA were detected by RT-PCR in all cell lines. By immunohistochemistry, BMP-2 protein expression was positive in 45% (5 out of 11) of cell lines. 36.4% (4 out of 11) were positive for type IV collagen. PBs-forming NK-211 was intensively positive for both BMP-2 and type IV collagen. In addition, NK-211 demonstrated extremely slow growth with a doubling time of 450 hours. In surgical specimens, BMP-2 vs. type IV collagen positivities in tumor cells were 100% (20 out of 20) vs. 40% (8 out of 20) in SA with PBs, 61.1% (11 out of 18) vs. 0% (0 out of 18) in SA without PBs and 75% (9 out of 12) vs. 0% (0 out of 12) in MA. In PBs themselves, 100% (20 out of 20) positivity for BMP-2 and 80% (16 out of 20) for type IV collagen was shown. These results raise the possibility that BMP-2 and type IV collagen-producing slow growing tumor cells form PBs in ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11497252

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  MicroRNA miR-196a is a central regulator of HOX-B7 and BMP4 expression in malignant melanoma.

Authors:  Simone Braig; Daniel W Mueller; Tanja Rothhammer; Anja-Katrin Bosserhoff
Journal:  Cell Mol Life Sci       Date:  2010-05-18       Impact factor: 9.261

Review 2.  The Yin and Yang of bone morphogenetic proteins in cancer.

Authors:  Ashok Singh; Rebecca J Morris
Journal:  Cytokine Growth Factor Rev       Date:  2010-08-04       Impact factor: 7.638

3.  Association between collagen type XI α1 gene polymorphisms and papillary thyroid cancer in a Korean population.

Authors:  Hae Jeong Park; Bong-Keun Choe; Su Kang Kim; Hyun-Kyung Park; Jong Woo Kim; Joo-Ho Chung; Il Ki Hong; Dae Han Chung; Kee Hwan Kwon
Journal:  Exp Ther Med       Date:  2011-07-14       Impact factor: 2.447

4.  Expression of bone morphogenetic protein-2 and its receptors in epithelial ovarian cancer and their influence on the prognosis of ovarian cancer patients.

Authors:  Ying Ma; Lin Ma; Quan Guo; Shulan Zhang
Journal:  J Exp Clin Cancer Res       Date:  2010-06-30

5.  Differential gene expression in ovarian carcinoma: identification of potential biomarkers.

Authors:  Kathleen Hibbs; Keith M Skubitz; Stefan E Pambuccian; Rachael C Casey; Kathryn M Burleson; Theodore R Oegema; Jeannine J Thiele; Suzanne M Grindle; Robin L Bliss; Amy P N Skubitz
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

Review 6.  Multiple Pathways for Pathological Calcification in the Human Body.

Authors:  Netta Vidavsky; Jennie A M R Kunitake; Lara A Estroff
Journal:  Adv Healthc Mater       Date:  2020-12-04       Impact factor: 9.933

7.  Small putative NANOG, SOX2, and SSEA-4-positive stem cells resembling very small embryonic-like stem cells in sections of ovarian tissue in patients with ovarian cancer.

Authors:  Irma Virant-Klun; Natasa Kenda-Suster; Spela Smrkolj
Journal:  J Ovarian Res       Date:  2016-03-03       Impact factor: 4.234

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.